Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals

被引:2
作者
Khatib, Rasha [1 ]
Yeh, Eric J. [2 ]
Glowacki, Nicole [1 ]
McGuiness, Catherine B. [3 ]
Xie, Handing [4 ]
Wade, Rolin L. [4 ]
Kalich, Bethany A. [5 ]
Li, Yi [6 ]
Rifai, Abdelhadi [7 ]
Sawlani, Neal [8 ]
机构
[1] Advocate Aurora Hlth, Advocate Aurora Res Inst, Acad Res & Strateg Partnership, 3075 Highland Pkwy,Suite 600, Downers Grove, IL 60515 USA
[2] Amgen Inc, Global Hlth Econ & Outcomes Res HEOR, Thousand Oaks, CA USA
[3] IQVIA, Hlth Econ & Outcomes Res, Real World Evidence, Wayne, PA USA
[4] IQVIA, Wayne, PA USA
[5] Amgen Inc, Thousand Oaks, CA USA
[6] IQVIA, R&D Solut, Bloomington, IL USA
[7] Cheyenne Reg Med Grp, Heart & Vasc Inst, Cheyenne, WY USA
[8] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
来源
CLINICAL EPIDEMIOLOGY | 2023年 / 15卷
关键词
lipid-lowering therapy; high-intensity statin; acute coronary syndrome; real-world data; prescribing; adherence; MYOCARDIAL-INFARCTION; UNITED-STATES; CHOLESTEROL; ADULTS; TRENDS; RISK;
D O I
10.2147/CLEP.S400903
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: Clinical practice guidelines recommend initiating a high-intensity LLT and continued monitoring of low-density lipoprotein cholesterol (LDL-C) following acute coronary syndrome (ACS). We used real-world data to describe LLT utilization after discharge and 1-year adherence. The reduction in LDL-C was also evaluated.Methods: Data were extracted from electronic health records (EHRs) from 12 hospitals in a large community healthcare system in midwestern United States between 2013 and 2019. Data on eligible patients recently discharged with an ACS event were linked to pharmacy claims data to describe LLT fill rates and 1-year post-discharge adherence. Adherence was reported as the proportion of days covered >= 80%.Results: Of the 10,589 eligible patients, 49% filled a high-intensity statin at discharge and only 36% were adherent at 1 year. The mean (SD) age was 66.1 +/- 13.3, 39.3% were females, 58.8% were Caucasian, and 53.0% had Medicare. There was a clear trend for greater fill rates at discharge among patients with higher LDL-C values than those with lower values (p<0.01). Key predictors of high -intensity (versus medium-intensity) LLT use within 21 days after an ACS event included ACS type (odds ratio [OR] 0.59; 95% confidence interval [CI] 0.52-0.67 for NSTEMI versus STEMI), age group (OR: 0.59; 95% CI: 0.48-0.72 for >75 years versus <65 years), and statin use before index ACS event (OR: 1.56; 95% CI: 1.23-1.88).Conclusion: This real-world study found that despite recommendations in clinical practice guidelines, high-intensity LLT fill rates at discharge and 1-year adherence to LLT remain suboptimal. Clinical characteristics, including ACS type and LDL-C values, were strong predictors of filling and adherence to guideline-recommended therapy. Age, sex, and race/ethnicity disparities were observed in discharge fill rates and 1-year adherence. These results highlight the need for continued efforts at the patient and provider levels to improve LLT adherence among ACS patients.
引用
收藏
页码:547 / 557
页数:11
相关论文
共 50 条
  • [21] Addition of Ezetimibe to Intensive Lipid-Lowering Therapy Is Associated With a Lower Incidence of Heart Failure in Patients With Acute Coronary Syndrome
    Yoshikawa, Masafumi
    Honda, Atsushi
    Arashi, Hiroyuki
    Shibahashi, Eiji
    Otsuki, Hisao
    Kawada-Watanabe, Erisa
    Ogawa, Hiroshi
    Yamaguchi, Junichi
    Hagiwara, Nobuhisa
    CIRCULATION JOURNAL, 2024, 88 (11) : 1819 - 1824
  • [22] Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
    Yamashita, Satoshi
    Sakamoto, Atsushi
    Shoji, Satoshi
    Kawaguchi, Yoshitaka
    Wakabayashi, Yasushi
    Matsunaga, Masaki
    Suguro, Kiyohisa
    Matsumoto, Yuji
    Takase, Hiroyuki
    Onodera, Tomoya
    Tawarahara, Kei
    Muto, Masahiro
    Shirasaki, Yasutaka
    Katoh, Hideki
    Sano, Makoto
    Suwa, Kenichiro
    Naruse, Yoshihisa
    Ohtani, Hayato
    Saotome, Masao
    Urushida, Tsuyoshi
    Kohsaka, Shun
    Okada, Eisaku
    Maekawa, Yuichiro
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (05)
  • [23] Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    Dai, Yun-Yan
    Zhang, Hai-Shan
    Zhang, Xin-Gang
    Guan, Qi-Gang
    Gao, Yuan
    Li, Yu-Ze
    Zhang, Yue-Lan
    Jia, Da-Lin
    Sun, Ying-Xian
    Qi, Guo-Xian
    Tian, Wen
    JOURNAL OF THORACIC DISEASE, 2017, 9 (05) : 1345 - 1352
  • [24] Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial
    Zafeiropoulos, Stefanos
    Farmakis, Ioannis
    Kartas, Anastasios
    Arvanitaki, Alexandra
    Pagiantza, Areti
    Boulmpou, Aristi
    Tampaki, Athina
    Kosmidis, Diamantis
    Nevras, Vassileios
    Markidis, Eleftherios
    Papadimitriou, Ioannis
    Vlachou, Anastasia
    Arvanitakis, Konstantinos
    Miyara, Santiago J.
    Ziakas, Antonios
    Molmenti, Ernesto P.
    Kassimis, George
    Zanos, Stavros
    Karvounis, Haralambos
    Giannakoulas, George
    ATHEROSCLEROSIS, 2021, 323 : 37 - 43
  • [25] Impact of an Intensive Lipid-Lowering Therapy Protocol on Achieving Target Low-Density Lipoprotein Cholesterol Levels in Patients With Acute Coronary Syndrome
    Seiyama, Kosuke
    Oka, Akihiro
    Miyoshi, Toru
    Sudo, Yuya
    Takagi, Wataru
    Ugawa, Satoko
    Okada, Tomoaki
    Nosaka, Kazumasa
    Doi, Masayuki
    CIRCULATION REPORTS, 2025, 7 (02) : 131 - 138
  • [26] Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II
    Gitt, Anselm K.
    Lautsch, Dominik
    Ferrieres, Jean
    De Ferrari, Gaetano M.
    Vyas, Ami
    Baxter, Carl A.
    Bash, Lori D.
    Ashton, Veronica
    Horack, Martin
    Almahmeed, Wael
    Chiang, Fu-Tien
    Poh, Kian Keong
    Brudi, Philippe
    Ambegaonkar, Baishali
    ATHEROSCLEROSIS, 2017, 266 : 158 - 166
  • [27] Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study
    Marie Skov Kristensen
    Anders Green
    Mads Nybo
    Simone Møller Hede
    Kristian Handberg Mikkelsen
    Gunnar Gislason
    Mogens Lytken Larsen
    Annette Kjær Ersbøll
    BMC Cardiovascular Disorders, 20
  • [28] Red Yeast Rice and Statin Therapy in Patients with Hypercholesterolemia and the Comorbidities: A Retrospective Cohort Study on Lipid-Lowering Effects and Cardiovascular Outcomes
    Hsueh, Tun-Pin
    Lin, Wan-Ling
    Hu, Wen-Long
    Hung, Yu-Chiang
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2024, 52 (02): : 417 - 432
  • [29] Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study
    Punekar, Rajeshwari S.
    Fox, Kathleen M.
    Paoli, Carly J.
    Richhariya, Akshara
    Cziraky, Mark J.
    Gandra, Shravanthi R.
    Toth, Peter P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (05) : 869 - 876
  • [30] Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes From the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Trial
    Murphy, Sabina A.
    Cannon, Christopher P.
    Wiviott, Stephen D.
    McCabe, Carolyn H.
    Braunwald, Eugene
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (25) : 2358 - 2362